Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients

Key facts

Sponsor

Actinium Pharmaceuticals

Principal Investigator

Avinash Desai, MD

Actinium Pharmaceuticals Inc.

Intervention

Cytarabine (Phase 1 only)(drug)

Enrollment

40 enrolled

Eligibility

60 years · All sexes

Timeline

2012 – 2020

Study locations (17)

• UCLA Medical Center, Division of Hematology/Oncology, Los Angeles, California, United States
• University of Kentucky, Markey Cancer Center, Lexington, Kentucky, United States
• University of Louisville, James Graham Brown Cancer Center, Louisville, Kentucky, United States
• Ochsner Medical Center, The Gayle and Tom Benson Cancer Center, New Orleans, Louisiana, United States
• Mayo Clinic, Rochester, Minnesota, United States
• Weill Medical College of Cornell University, New York, New York, United States
• Columbia University Medical, Herbert Irving Comprehensive Cancer Center, New York, New York, United States
• Memorial Sloan Kettering Cancer Center, New York, New York, United States
• Duke Cancer Center, Durham, North Carolina, United States
• University of Pennsylvania, Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States
• St. Francis Cancer Center, Greenville, South Carolina, United States
• Baylor Scott and White Research Institute, Charles A. Sammons Cancer Center, Dallas, Texas, United States
• Swedish Cancer Institute, Center for Blood Disorders and Stem Cell Transplantation, Seattle, Washington, United States
• Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
• West Virginia University, Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States
• +2 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT06303193
  Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
  National Cancer Institute (NCI)
• RECRUITINGNANCT07500753
  A Single-arm, Prospective Study of a Cladribine-Bridged LABU Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory MDS/AML in Elderly Patients
  The First Affiliated Hospital of Soochow University
• RECRUITINGPHASE3NCT07422480
  A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
  Takeda
• RECRUITINGPHASE4NCT07486713
  Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
  Rigel Pharmaceuticals
• RECRUITINGPHASE1NCT07107126
  Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
  Remedy Plan, Inc.
• RECRUITINGPHASE1NCT07270978
  Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
  University of Virginia
• RECRUITINGNANCT06781099
  Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis
  Hospices Civils de Lyon
• RECRUITINGPHASE2NCT07228273
  Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
  OHSU Knight Cancer Institute

See all trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent →